Serum Leptin Levels in Treatment-Naive Patients with Clinically Isolated Syndrome or Relapsing-Remitting Multiple Sclerosis

被引:21
|
作者
Evangelopoulos, Maria Eleftheria [1 ]
Koutsis, Georgios [1 ]
Markianos, Manolis [1 ]
机构
[1] Univ Athens, Eginit Hosp, Sch Med, Dept Neurol, 74 Vassilisis Sophias Ave, Athens 11528, Greece
关键词
D O I
10.1155/2014/486282
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Several studies have investigated leptin levels in patients with multiple sclerosis (MS) with somewhat conflicting results. They have all focused on patients with established relapsing-remitting (RR) MS but have not specifically looked at patients with clinically isolated syndrome (CIS) suggestive of MS, in the early stages of disease. In this study, serum leptin levels were measured in 89 treatment-naive patients with CIS (53 patients) or RRMS (36 patients) and 73 controls searching for differences between the groups and for associations with several disease parameters. The expected significant sexual dimorphism in leptin levels (higher levels in females) was observed in both MS patients and controls. Increased leptin levels were found in female patients with RRMS compared to female controls (P = .003) and female CIS patients (P = .001). Female CIS patients had comparable levels to controls. Leptin levels correlated positively to disease duration, but not to EDSS, in female patients with RRMS. The results of the present study do not indicate involvement of leptin in the early stages of MS. Normal leptin levels in patients with CIS suggest that leptin does not have a pathogenic role. The ratio leptin/BMI increases during disease course in female MS patients in a time-dependent and disability-independent manner.
引用
收藏
页数:6
相关论文
共 50 条
  • [31] Daclizumab for the treatment of relapsing-remitting multiple sclerosis
    Herwerth, Marina
    Hemmer, Bernhard
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2017, 17 (06) : 747 - 753
  • [32] Alemtuzumab in the treatment of relapsing-remitting multiple sclerosis
    Fox, Edward J.
    EXPERT REVIEW OF NEUROTHERAPEUTICS, 2010, 10 (12) : 1789 - 1797
  • [33] Alemtuzumab for the treatment of relapsing-remitting multiple sclerosis
    Hersh, Carrie M.
    Cohen, Jeffrey A.
    IMMUNOTHERAPY, 2014, 6 (03) : 249 - 259
  • [34] Ocrelizumab for the treatment of relapsing-remitting multiple sclerosis
    Menge, Til
    Dubey, Divyanshu
    Warnke, Clemens
    Hartung, Hans-Peter
    Stuve, Olaf
    EXPERT REVIEW OF NEUROTHERAPEUTICS, 2016, 16 (10) : 1131 - 1139
  • [35] Mitoxantrone treatment in patients with early relapsing-remitting multiple sclerosis
    Cocco, E.
    Marchi, P.
    Sardu, C.
    Russo, P.
    Paolillo, A.
    Mascia, M. G.
    Solla, M.
    Frau, J.
    Lorefice, L.
    Massole, S.
    Floris, G.
    Marrosu, M. G.
    MULTIPLE SCLEROSIS JOURNAL, 2007, 13 (08) : 975 - 980
  • [36] Considerations in the treatment of relapsing-remitting multiple sclerosis
    Calabresi, PA
    NEUROLOGY, 2002, 58 (08) : S10 - S22
  • [37] Teriflunomide for the treatment of relapsing-remitting multiple sclerosis
    Miller, Aaron E.
    EXPERT REVIEW OF CLINICAL IMMUNOLOGY, 2015, 11 (02) : 181 - 194
  • [38] Ponesimod for the treatment of relapsing-remitting multiple sclerosis
    Gaber, Tarek A-Z K.
    Eltemamy, Marwa
    PROGRESS IN NEUROLOGY AND PSYCHIATRY, 2022, 26 (02) : 18 - 19
  • [39] Histogram analysis of diffusion measures in clinically isolated syndromes and relapsing-remitting multiple sclerosis
    Yu, Chun Shui
    Lin, Fu Chun
    Liu, Yaou
    Duan, Yunyun
    Lei, Hao
    Li, Kun Cheng
    EUROPEAN JOURNAL OF RADIOLOGY, 2008, 68 (02) : 328 - 334
  • [40] Brain atrophy in clinically early relapsing-remitting multiple sclerosis
    Chard, DT
    Griffin, CM
    Parker, GJM
    Kapoor, R
    Thompson, AJ
    Miller, DH
    BRAIN, 2002, 125 : 327 - 337